Join
Live feed
·
PRReleasevia Quantisnow
BridgeBio Oncology Therapeutics Inc. logo

BBOT Presents Preclinical Data Showing RAS:PI3Kα Breaker BBO-10203 Inhibits PI3Kα/AKT Signaling in HER2AMP Models at the AACR Annual Meeting 2026

ByQuantisnow·Wall Street's wire, on your screen.
BBOT· BridgeBio Oncology Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track BBOT (BridgeBio Oncology Therapeutics Inc.) and more on Quantisnow.